-
Development Pipeline
Development-stage programs in gout, cancer and HIV -
Gout
First and next-generation URAT1 transporter inhibitors for the treatment of hyperuricemia and gout -
Cancer
Mitogen-activated ERK kinase (MEK) inhibitors for the treatment of cancer, being developed under a global license agreement with Bayer Healthcare AG -
HIV
First and next-generation non-nucleoside reverse transcriptase inhibitors (NNRTIs), for the treatment of HIV
Scientific Publications
Scientific publications, posters and presentations relating to Ardea Biosciences’ proprietary research programs or research collaborations with other biotechnology or pharmaceutical companies will be posted once they are available.
Company Presentations |
|
 |
Ardea Company Update, August 6, 2010 |
Latest News
- 06 Aug 2010 Ardea Biosciences Reports Recent Accomplishments and Second Quarter 2010 Financial Results
- 21 Jun 2010 Ardea Biosciences to Present at the Fifth Annual Piper Jaffray Europe Conference
- 18 Jun 2010 Positive Phase 2 Data on RDEA594, Ardea Biosciences' Lead Product Candidate for the Treatment of Hyperuricemia and Gout, Presented at the Annual European Congress of Rheumatology
Upcoming Events
There are currently no upcoming events scheduled.